Synapse - Nancy Sklarin

Results (23)

TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR-metastatic breast cancer (MBC)

Meeting Abstract

Gucalp, A.; Tolaney, S. M.; Isakoff, S. J.; Ingle, J. N.; Liu, M. C.; Carey, L. A.; Blackwell, K. L.; Rugo, H. S.; Nabell, L.; Abbruzzi, A.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

Journal Article

Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study

Meeting Abstract

Murphy, C.; Mallam, D.; Stein, S.; Patil, S.; Howard, J.; Sklarin, N. T.; Gemignani, M.; Hudis, C.; Seidman, A. D.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
Cancer Research (2010)

Fulltext@MSK | Save

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer

Journal Article

Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
Clinical Breast Cancer (2010)

Fulltext@MSK | Save

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer

Journal Article

Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)